Although Philadelphia chromosome-positive acute leukemia (Ph⁺-ALL) has been revolutionized with tyrosine kinase inhibitors (TKIs), resistance and mutation are universal events during treatment with first-generation and second-generation TKIs. The present third-generation TKI has a dose-dependent, increased risk of serious cardiovascular events and the sensitivity is poor for patients with ≥2 mutations accompanied by the T315I mutation. Thus, novel and well-tolerated TKIs should be explored. This study analyzes the efficacy and advert effects of olverembatinib, a novel third TKI, in the treatment of newly diagnosed adult Ph⁺-ALL in induction therapy. Four adult patients with newly diagnosed Ph⁺-ALL were treated with olverembatinib as the first-line treatment. For induction therapy, these patients received 40 mg of oral olverembatinib quaque omni die for 28 days, 1 mg/kg/d of prednisone for 14 days, then tapered and stopped at 28 days and vindesine 4 mg/d at days 1, 8 and 15. After induction therapy, these patients received median or high-dose of cytarabine and methotrexate combined with oral olverembatinib as consolidation therapy. Then the allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed. All patients reached complete remission with a complete cytogenetic response after induction therapy. Two patients reached major molecular remission and one with complete molecular remission. Before allo-HSCT, all the patients achieved complete molecular remission. All the patients have survived disease-free for 3–6 months. No severe advert effects were observed. It is well-tolerated and effective for olverembatinib in the treatment of newly diagnosed adult patients with Ph⁺-ALL. A prospective study should be performed to further testify the role.

尽管酪氨酸激酶抑制剂 (TKI) 彻底改变了费城染色体阳性急性白血病 (Ph ⁺ -ALL)，但第一代和第二代 TKI 治疗过程中普遍存在耐药和突变事件。目前的第三代TKI具有剂量依赖性，严重心血管事件的风险增加，并且对于≥2个突变伴有T315I突变的患者敏感性较差。因此，应探索新型且耐受性良好的 TKI。本研究分析了新型第三种 TKI olverembatinib 在诱导治疗中治疗新诊断成人 Ph ⁺ -ALL 的疗效和广告效果。四名新诊断为 Ph ⁺ -ALL 的成年患者接受了 olverembatinib 作为一线治疗。对于诱导治疗，这些患者接受口服 olverembatinib quaqueomni 40 毫克，持续 28 天，泼尼松 1 毫克/公斤/天，持续 14 天，然后逐渐减量并在第 28 天停止，长春地辛 4 毫克/天，在第 1、8 天和15.诱导治疗后，这些患者接受中剂量或高剂量的阿糖胞苷和甲氨蝶呤联合口服olverembatinib作为巩固治疗。然后进行同种异体造血干细胞移植（allo-HSCT）。所有患者在诱导治疗后均达到完全缓解并具有完整的细胞遗传学反应。两名患者达到主要分子学缓解，一名患者达到完全分子学缓解。在allo-HSCT前，所有患者均达到完全分子缓解。所有患者均无病生存3-6个月。没有观察到严重的广告效应。 olverembatinib 在治疗新诊断的成年 Ph ⁺ -ALL 患者中具有良好的耐受性和有效性。 应进行前瞻性研究以进一步证明其作用。